[REVISION HISTORY]

FTC lawsuit against Hims & Hers

Updated 3 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-11 12:41 UTC → 2026-08-18 21:28 UTC · added ~~removed~~

In late July 2026, the U.S. Federal Trade Commission, alongside the attorneys general of California, Utah, and Los Angeles County, filed a lawsuit against telehealth provider Hims & Hers Health. The complaint alleged that the company used tracking technologies and customer lists to share sensitive health information with online advertisers Meta Platforms and Snap without consent, violating privacy promises. The company denied the allegations, calling the suit “baseless” and stating it would defend itself vigorously. Regulators also accused the firm of deceptive billing and false advertising. Specific allegations included charging for prescriptions before medical consultations, using misleading language such as “Pay $0 today” while burying terms in small print, and enrolling users in recurring subscriptions through unclear mechanisms. FTC Bureau of Consumer Protection director Christopher Mufarrige described the practices as “troubling,” noting that consumers were unknowingly locked into subscriptions and had faced difficult multi-step cancellation processes. By August 2026, Hims & Hers reported second-quarter revenue of approximately $753 million, a 38% year-over-year increase that exceeded market expectations. ~~The subscriber base grew by 19% to nearly 2.9 million.~~ However, the company reported a net loss of $0.37 per share, wider than ~~the $0.01 loss analysts had anticipated. This decline in profitability was~~ anticipated, attributed to aggressive expansion ~~into international markets~~ and branded GLP-1 ~~weight-loss~~ drugs. While the company raised its full-year revenue ~~guidance to between $3.1 billion and $3.3 billion,~~ guidance, its stock faced downward pressure due to ~~shrinking margins and~~ the “new legal overhang” created by the FTC lawsuit. On August 18, 2026, CEO Andrew Dudum publicly rejected the FTC allegations, characterizing the legal action as a “misunderstanding of how the company is modernizing healthcare through a digital ecosystem.” Dudum defended the business model as a necessary disruption of traditional healthcare and suggested the FTC might be prioritizing headlines over reaching a genuine settlement.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.